Gilbert M. Rishton Email & Phone Number

Honolulu, Hi - Hawaii, Us

At Cardax we've developed highly bioavailable formulations and novel derivatives of xanthophyll carotenoid anti-inflammatory agents including astaxanthin (ZanthoSyn, CDX-085), orally bioavailable and brain-penetrant anti-inflammatory agents that lower IL-1, IL-6, TNF, and CRP to treat and prevent age-related inflammatory diseases including cardiovascular disease and cognitive decline, and prevent neuroinflammation driving traumatic brain injury and Alzheimer's disease. The Cardax team has achieved successful launch of ZanthoSyn, the optimally formulated dietary supplement (astaxanthin, 12 mg) with superior oral absorption. Astaxanthin treats and prevents the low level systemic inflammation that drives chronic, progressive diseases of aging. Astaxanthin is anti-aging and promotes longevity via the FOXO3 pathway. Our novel and water-dispersible prodrug derivatives have been developed as drug candidates for cardiovascular disease and for the treatment of 'cytokine storm' observed in severe COVID-19 cases.

Purchase, New York, Us

Develop blood-brain barrier permeable small molecule antagonists of the synaptotoxic forms of soluble beta-amyloid oligomer (AbO) for Alzheimer’s disease (CT1812). CT1812 Alzheimer's. CT1812 structure. Conditioned extraction (CE) chemistry platform produced three promising drug lead series including our Phase II asset CT1812 WO2015116923 Our drug candidate CT1812 is currently being studied in Alzheimer's disease patients. Elayta CT1812 SPARC SNAP SHINE SEQUEL Alzheimer's synaptotoxic amyloid oligomer displacement amyloid oligomer drug alzheimer's disease amyloid oligomer drug alzheimer's disease amyloid oligomer drug alzheimer's disease amyloid oligomer drug alzheimer's disease CT1812 Alzheimer's. CT1812 structure Elayta patent elayta structure elayta patent elayta structure elayta patent elayta structure elayta alzheimer's elayta WO2015116923 amyloid oligomer displacing CT1812 Alzheiemer's CT1812 Alzheimer's CT1812 trial CT1812 structure CT1812 trial CT1812 clinical trial CT1812 Anti-Aβ Oligomer Drug Anti-Aβ Oligomer Drug Elayta CT1812 SPARC SNAP SHINE SEQUEL amyloid oligomer clearance amyloid oligomer displacing drug amyloid oligomer displacement CT1812 trial CT1812 patent CT1812 structure CT1812 Alzheimer's CT1812 CT1812 alzheimer's trial CT1812 CT1812 structure CT1812 patent CT1812 trial CT1812 structure CT1812 patent CT1812 trial CT1812 structure CT1812 patent CT1812 trial CT1812 structure CT1812 patent Elayta target engagement biomarkers cog201 shine cog105 sparc Elayta mechanism of action sigma-2 receptor complex proteins TMEM97 PGRMC1 PirB/LilRB2 elayta alzheimer's trial Elayta CT1812 SPARC SNAP SHINE SEQUEL Elayta CT1812 SPARC SNAP SHINE SEQUEL alzheimer's trial Elayta CT1812 SPARC SNAP SHINE SEQUEL Elayta CT1812 SPARC SNAP SHINE SEQUEL Elayta CT1812 SPARC SNAP SHINE SEQUEL alzheimer's trial snap sparc shine elayta alzheimer's trial snap sparc shine elayta AbO Abeta oligomer snap sparc shine

Raised funds from corporate and private donors for support of research in Alzheimer's disease drug discovery at California State University, Channel Islands. Focus on preventing neurodegeneration and stimulating neurogenesis and/or gliagenesis. Inhibition of the secretase enzymes and also the study of dietary antioxidants that effect neural stem cell proliferation and differentiation in neuronal systems. Developed proprietary method known as conditioned extraction (CE) to produce libraries of CNS druglike molecules (natural and unnatural) derived from SFE extracts including ginger oil turmeric oil CT1812 structure CT1812 Alzheimer's CT1812 clinical trial CT1812 Alzheimer's CT1812 drug trial CT1812 trial amyloid oligomer displacing drug amyloid oligomer displacement conditioned extraction ginger conditioned extraction turmeric conditioned extraction argan conditioned extraction CT1812 Alzheimer's supercritical fluid extracts medicinal chemistry los angeles elayta structure elayta patent elayta CT1812 alzheimer's elayta cognition therapeutics CT1812 structure CT1812 patent CT1812 alzheimer's CT1812 neuroinflammation drug neuroinflammation drug neuroinflammation drug Cognition Therapeutics Elayta Cognition Therapeutics ElaytaElayta Cognition Therapeutics Elayta Cognition Therapeutics Elayta Cognition Therapeutics Elayta Cognition Therapeutics Elayta elayta sparc elayta snap elayta clinical trial elayta sparc elayta snap elayta clinical trial elayta sparc elayta snap elayta clinical trial elayta sparc elayta patent elayta patent elayta patent elayta patent elayta patent elayta structure elayta structure elayta structure elayta structure elayta sparc elayta snap elayta clinical trial elayta ct1812 structure ct1812 patent ct1812 structure ct1812 patent ct1812 structure ct1812 patent elayta structure elayta patent elayta structure elayta patent elayta structure elayta patent elayta structure elayta patent ct1812 structure elayta sparc elayta snap elayta clinical trial

Thousand Oaks, Ca, Us

First medicinal chemist at the Thousand Oaks site. Managed Small Molecule drug Discovery program initiation. Directly involved in recruiting 50 medicinal chemists over our first 2 years. Managed medicinal chemistry programs therapeutic areas in programs including Alzheimer's disease (gamma- and beta-secretase), inflammation and cancer. I was the chemistry manager for the preclinical development and clinical development including CMC activities for AMG-073 Sensipar (Cinacalcet). Sensipar (Cinacalcet) was launched in 2004 for treatment and prevention of hyperparathyroidism, particularly for patients in the kidney dialysis arena. Sensipar (Cinacalcet) now earns annual revenues exceeding $1.3B. Alzheimer's drug discovery leadlikeness druglikeness false positives leadlike druglike false positives Sensipar (Cinacalcet) amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug amyloid oligomer displacing drug CDX-085 longevity ZanthoSyn longevity CDX-085 healthspan ZanthoSyn healthspan CDX-085 anti-aging ZanthoSyn anti-aging CDX-085 longevity ZanthoSyn longevity CDX-085 healthspan ZanthoSyn healthspan CDX-085 anti-aging ZanthoSyn anti-aging astaxanthin longevity astaxanthin longevity astaxanthin healthspan astaxanthin healthspan astaxanthin anti-aging astaxanthin anti-aginghttps://www.amgen.com

Medicinal chemistry and peptidomimetic chemistry en route to antagonists of cell adhesion via the alpha4beta1 pathway for inflammatory disease including rheumatoid arthritis and asthma. Our project resulted in a partnership with Upjohn sharing worldwide marketing rights of a series of alpha4beta1 antagonists. Arg-Gly-Asp (RGD) peptidomimetics.

Post-Doc, Prof. Larry E. Overman, Asymmetric Organic Synthesis

Doctor Of Philosophy (Ph.D.), Organic Chemistry, Organic Synthesis, Morphinan Synthesis Under Martin A. Schwartz

Bs, Chemistry